PET/CT for patients with breast cancer: where is the clinical impact?
GA Ulaner - American Journal of Roentgenology, 2019 - Am Roentgen Ray Soc
OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …
settings, including initial staging, treatment response assessment, and evaluation of …
[PDF][PDF] Cancers du sein
D Groheux, E Hindié, PY Salaün - Médecine Nucléaire, 2019 - Elsevier
▪ Étapes du parcours de soins concernées: diagnostic positif et caractérisation tumorale,
évaluation de la multifocalité et du score T, évaluation du statut axillaire, bilan d'extension …
évaluation de la multifocalité et du score T, évaluation du statut axillaire, bilan d'extension …
[PDF][PDF] Comportamiento de la glucosa y la 18 F-FDG en tumores malignos, con enfoque en el cáncer de mama.
CR Luis, MD Lupera Hernán, TJ MD, AJ MD, E MD - docs.bvsalud.org
El subtipo histológico, el estado del receptor y otros factores biológicos, afectan en gran
medida la avidez de la neoplasia mamaria en la tomografía por emisión de positrones (PET …
medida la avidez de la neoplasia mamaria en la tomografía por emisión de positrones (PET …
Clinical Utility of PET/CT in Breast Cancer Management and Targeted Therapy
X Hao, X Meng, Z Wu - Nuclear Medicine in Oncology: Molecular Imaging …, 2019 - Springer
Breast cancer is currently the most prevalent malignant disease affecting women's health.
Breast cancer is a highly heterogeneous tumor, comprising multiple entities associated with …
Breast cancer is a highly heterogeneous tumor, comprising multiple entities associated with …